Oppenheimer & Co. Inc. decreased its position in Pfizer, Inc. (NYSE:PFE) by 0.2% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 750,562 shares of the biopharmaceutical company’s stock after selling 1,315 shares during the period. Pfizer makes up approximately 0.7% of Oppenheimer & Co. Inc.’s investment portfolio, making the stock its 18th largest position. Oppenheimer & Co. Inc.’s holdings in Pfizer were worth $25,676,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. Logan Capital Management Inc. boosted its stake in shares of Pfizer by 3.3% in the first quarter. Logan Capital Management Inc. now owns 505,578 shares of the biopharmaceutical company’s stock worth $17,296,000 after buying an additional 16,001 shares in the last quarter. Edmond DE Rothschild Holding S.A. boosted its stake in shares of Pfizer by 2.6% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 3,048,969 shares of the biopharmaceutical company’s stock worth $104,305,000 after buying an additional 76,594 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of Pfizer by 1.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 31,260,823 shares of the biopharmaceutical company’s stock worth $1,069,433,000 after buying an additional 377,404 shares in the last quarter. Brown Advisory Securities LLC boosted its stake in shares of Pfizer by 6.8% in the first quarter. Brown Advisory Securities LLC now owns 60,015 shares of the biopharmaceutical company’s stock worth $2,054,000 after buying an additional 3,825 shares in the last quarter. Finally, Good Life Advisors LLC boosted its stake in shares of Pfizer by 24.7% in the first quarter. Good Life Advisors LLC now owns 18,348 shares of the biopharmaceutical company’s stock worth $624,000 after buying an additional 3,629 shares in the last quarter. Hedge funds and other institutional investors own 70.10% of the company’s stock.

Shares of Pfizer, Inc. (PFE) traded up 0.2995% during midday trading on Friday, hitting $33.5201. 3,540,044 shares of the stock were exchanged. The stock has a market cap of $200.04 billion, a P/E ratio of 24.5209 and a beta of 1.00. The stock’s 50-day moving average price is $33.43 and its 200 day moving average price is $33.30. Pfizer, Inc. has a one year low of $29.83 and a one year high of $35.38.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The company had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a return on equity of 24.11% and a net margin of 15.84%. The firm’s quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.64 EPS. On average, analysts anticipate that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.83%. Pfizer’s dividend payout ratio is 94.12%.

WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.watchlistnews.com/oppenheimer-co-inc-sells-1315-shares-of-pfizer-inc-pfe/1475354.html.

A number of brokerages recently weighed in on PFE. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 5th. Jefferies Group LLC set a $35.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. BMO Capital Markets upgraded shares of Pfizer from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $33.00 to $37.00 in a research note on Wednesday, August 2nd. Berenberg Bank set a $39.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, August 1st. Finally, UBS AG restated a “buy” rating and issued a $38.00 target price on shares of Pfizer in a research note on Monday, July 31st. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $37.77.

In other news, CEO Ian C. Read sold 96,950 shares of the company’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the transaction, the insider now owns 151,474 shares in the company, valued at approximately $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is owned by corporate insiders.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.